"Lactams, Macrocyclic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
LACTAMS forming compounds with a ring size of approximately 1-3 dozen atoms.
| Descriptor ID |
D047029
|
| MeSH Number(s) |
D02.065.589.327 D04.345.295
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Lactams, Macrocyclic".
Below are MeSH descriptors whose meaning is more specific than "Lactams, Macrocyclic".
This graph shows the total number of publications written about "Lactams, Macrocyclic" by people in this website by year, and whether "Lactams, Macrocyclic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2002 | 0 | 2 | 2 |
| 2004 | 0 | 1 | 1 |
| 2008 | 1 | 1 | 2 |
| 2011 | 1 | 1 | 2 |
| 2014 | 0 | 2 | 2 |
| 2015 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lactams, Macrocyclic" by people in Profiles.
-
Novel mechanism of cyclic nucleotide crosstalk mediated by PKG-dependent proteasomal degradation of the Hsp90 client protein phosphodiesterase 3A. J Biol Chem. 2024 10; 300(10):107723.
-
Lorlatinib Exposed: A Far From Optimal Dose. Clin Pharmacol Ther. 2022 06; 111(6):1195-1196.
-
The Major Heat Shock Proteins, Hsp70 and Hsp90, in 2-Methoxyestradiol-Mediated Osteosarcoma Cell Death Model. Int J Mol Sci. 2020 Jan 17; 21(2).
-
Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer. Cancer Res. 2018 12 15; 78(24):6866-6880.
-
The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy. Cancer Treat Rev. 2017 Apr; 55:181-189.
-
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discov. 2016 10; 6(10):1118-1133.
-
The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma. Cancer Discov. 2016 Jan; 6(1):96-107.
-
Molecular chaperone Hsp90 is a therapeutic target for noroviruses. J Virol. 2015 Jun; 89(12):6352-63.
-
An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014 Dec 18; 371(25):2375-82.
-
A system for the continuous directed evolution of proteases rapidly reveals drug-resistance mutations. Nat Commun. 2014 Oct 30; 5:5352.